Citations (65)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Rafaela Costa, Nuno G. Oliveira & Ricardo Jorge Dinis-Oliveira. (2019) Pharmacokinetic and pharmacodynamic of bupropion: integrative overview of relevant clinical and forensic aspects. Drug Metabolism Reviews 51:3, pages 293-313.
Read now
Read now
Jillissa C. Molnari & Alan L. Myers. (2012) Carbonyl reduction of bupropion in human liver. Xenobiotica 42:6, pages 550-561.
Read now
Read now
Yuan Chen, Hua-fen Liu, Liling Liu, Khanh Nguyen, Elliott B. Jones & Adrian J. Fretland. (2010) The in vitro metabolism of bupropion revisited: concentration dependent involvement of cytochrome P450 2C19. Xenobiotica 40:8, pages 536-546.
Read now
Read now
D. F. V. LEWIS, B. G. LAKE, M. DICKINS, P. J. EDDERSHAW, M. H. TARBIT & P. S. GOLDFARB. (1999) Molecular modelling of CYP2B6, the human CYP2B isoform, by homology with the substrate-bound CYP102 crystal structure: evaluation of CYP2B6 substrate characteristics, the cytochrome b5 binding site and comparisons with CYP2B1 and CYP2B4. Xenobiotica 29:4, pages 361-393.
Read now
Read now
Articles from other publishers (61)
Chandrali S. Bhattacharya, Andrea R. Masters, Christine Bach, Anthony L. Sinn, Melissa A. Trowbridge & Robert E. StratfordJr.Jr.. (2023) Characterization of the Stereoselective Disposition of Bupropion and Its Metabolites in Rat Plasma and Brain. European Journal of Drug Metabolism and Pharmacokinetics 48:2, pages 171-187.
Crossref
Crossref
Nadia O Bamfo, Jessica BL Lu & Zeruesenay Desta. (2023) Stereoselective Metabolism of Bupropion to Active Metabolites in Cellular Fractions of Human Liver and Intestine. Drug Metabolism and Disposition 51:1, pages 54-66.
Crossref
Crossref
Donald J. AbrahamRichard A. Glennon & Leslie Iversen. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
1
56
.
Pan-Fen Wang, Alicia Neiner & Evan D. Kharasch. (2020) Stereoselective Bupropion Hydroxylation by Cytochrome P450 CYP2B6 and Cytochrome P450 Oxidoreductase Genetic Variants. Drug Metabolism and Disposition 48:6, pages 438-445.
Crossref
Crossref
Montserrat Navarro, Kendall L. Luhn, Alexey B. Kampov‐Polevoy, James C. Garbutt & Todd E. Thiele. (2019)
Bupropion, Alone and in Combination with Naltrexone, Blunts Binge‐Like Ethanol Drinking and Intake Following Chronic Intermittent Access to Ethanol in Male C57
BL
/6J Mice
. Alcoholism: Clinical and Experimental Research 43:5, pages 783-790.
Crossref
Crossref
Chandrali Bhattacharya, Danielle Kirby, Michael Van Stipdonk & Robert E. Stratford. (2018) Comparison of In Vitro Stereoselective Metabolism of Bupropion in Human, Monkey, Rat, and Mouse Liver Microsomes. European Journal of Drug Metabolism and Pharmacokinetics 44:2, pages 261-274.
Crossref
Crossref
Emily R. Nicholson, Julian E. Dilley & Janice C. Froehlich. (2018) Co-Administration of Low-Dose Naltrexone and Bupropion Reduces Alcohol Drinking in Alcohol-Preferring (P) Rats. Alcoholism: Clinical and Experimental Research 42:3, pages 571-577.
Crossref
Crossref
Eunice Yuen, Steven Swanson & Jeffrey M. Witkin. (2017) Prediction of human efficacious antidepressant doses using the mouse forced swim test. Pharmacology Biochemistry and Behavior 161, pages 22-29.
Crossref
Crossref
John A. Rosecrans & Richard Young. 2018. The Behavioral Neuroscience of Drug Discrimination. The Behavioral Neuroscience of Drug Discrimination
51
94
.
Jennifer E. Sager, John R. Choiniere, Justine Chang, Alyssa Stephenson-Famy, Wendel L. Nelson & Nina Isoherranen. (2016) Identification and Structural Characterization of Three New Metabolites of Bupropion in Humans. ACS Medicinal Chemistry Letters 7:8, pages 791-796.
Crossref
Crossref
Aaron M. Teitelbaum, Alicia M. Flaker & Evan D. Kharasch. (2016) Development, validation and application of a comprehensive stereoselective LC/MS–MS assay for bupropion and oxidative, reductive, and glucuronide metabolites in human urine. Journal of Chromatography B 1027, pages 239-253.
Crossref
Crossref
A. R. Masters, B. T. Gufford, J. B. L. Lu, I. F. Metzger, D. R. Jones & Z. Desta. (2016) Chiral Plasma Pharmacokinetics and Urinary Excretion of Bupropion and Metabolites in Healthy Volunteers. Journal of Pharmacology and Experimental Therapeutics 358:2, pages 230-238.
Crossref
Crossref
Sonika Batra & Ravi Bhushan. (2015) Resolution of enantiomers of bupropion and its metabolites by liquid chromatography. Biomedical Chromatography 30:5, pages 670-682.
Crossref
Crossref
B. T. Gufford, J. B. L. Lu, I. F. Metzger, D. R. Jones & Z. Desta. (2016) Stereoselective Glucuronidation of Bupropion Metabolites In Vitro and In Vivo. Drug Metabolism and Disposition 44:4, pages 544-553.
Crossref
Crossref
E. Malcolm, F. I. Carroll, B. Blough, M. I. Damaj & M. Shoaib. (2015) Examination of the metabolite hydroxybupropion in the reinforcing and aversive stimulus effects of nicotine in rats. Psychopharmacology 232:15, pages 2763-2771.
Crossref
Crossref
Anne K. Laib, Sonja Brünen, Philippe Pfeifer, Philippe Vincent & Christoph Hiemke. (2014) Serum Concentrations of Hydroxybupropion for Dose Optimization of Depressed Patients Treated With Bupropion. Therapeutic Drug Monitoring 36:4, pages 473-479.
Crossref
Crossref
Jiake He, Yang Yu, Bhagwat Prasad, Xijing Chen & Jashvant D. Unadkat. (2014) Mechanism of an unusual, but clinically significant, digoxin-bupropion drug interaction. Biopharmaceutics & Drug Disposition 35:5, pages 253-263.
Crossref
Crossref
F. Ivy Carroll, Bruce E. Blough, S. Wayne Mascarella, Hernán A. Navarro, Ronald J. Lukas & M. Imad Damaj. 2014. Emerging Targets & Therapeutics in the Treatment of Psychostimulant Abuse. Emerging Targets & Therapeutics in the Treatment of Psychostimulant Abuse
177
216
.
Rohit Bansal, Balraj Saini, Yogita Bansal & Gulshan Bansal. (2013)
MS
n
, LC-MS-TOF and LC-PDA studies for identification of new degradation impurities of bupropion
. Biomedical Chromatography 27:11, pages 1387-1397.
Crossref
Crossref
Eric Sands. 2014. Handbook of Metabolic Pathways of Xenobiotics. Handbook of Metabolic Pathways of Xenobiotics
1
3
.
Arne Meyer, Anna Vuorinen, Agnieszka E. Zielinska, Petra Strajhar, Gareth G. Lavery, Daniela Schuster & Alex Odermatt. (2013)
Formation of Threohydrobupropion from Bupropion Is Dependent on 11
β
-Hydroxysteroid Dehydrogenase 1
. Drug Metabolism and Disposition 41:9, pages 1671-1678.
Crossref
Crossref
Katarina Ilic, Roy L. Hawke, Ranjit K. Thirumaran, Erin G. Schuetz, J. Heyward Hull, Angela D.M. Kashuba, Paul W. Stewart, Celeste M. Lindley & Mei-Ling Chen. (2013)
The Influence of Sex, Ethnicity, and
CYP2B6
Genotype on Bupropion Metabolism as an Index of Hepatic CYP2B6 Activity in Humans
. Drug Metabolism and Disposition 41:3, pages 575-581.
Crossref
Crossref
S. D. Grabus, F. I. Carroll & M. I. Damaj. (2012) Bupropion and its Main Metabolite Reverse Nicotine Chronic Tolerance in the Mouse. Nicotine & Tobacco Research 14:11, pages 1356-1361.
Crossref
Crossref
Samah S. Abbas, Mohamed R. Elghobashy, Rafeek F. Shokry & Lories I. Bebawy. (2012) Stability indicating HPLC and spectrophotometric methods for the determination of bupropion hydrochloride in the presence of its alkaline degradates and related impurity. Bulletin of Faculty of Pharmacy, Cairo University 50:1, pages 49-59.
Crossref
Crossref
Jillissa C. Molnari, Hazem E. Hassan & Alan L. Myers. (2011) Effects of sertraline on the pharmacokinetics of bupropion and its major metabolite, hydroxybupropion, in mice. European Journal of Drug Metabolism and Pharmacokinetics 37:1, pages 57-63.
Crossref
Crossref
Alexander V. LyubimovDeepak K. Dalvie. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
54
.
Dumrongsak Pekthong, Coraline Desbans, Hélène Martin & Lysiane Richert. (2012) Bupropion Hydroxylation as a Selective Marker of Rat CYP2B1 Catalytic Activity. Drug Metabolism and Disposition 40:1, pages 32-38.
Crossref
Crossref
Jillissa Christine Molnari, Hazem EmadEldin Hassan, Bryant Michael Moeller & Alan Lewis Myers. (2011) Drug Interaction Study between Bupropion and Ticlopidine in Male CF-1 Mice. Biological and Pharmaceutical Bulletin 34:3, pages 447-451.
Crossref
Crossref
Bartłomiej Barczyński, Grzegorz Buszewicz, Jarogniew J. Łuszczki, Krzysztof Bańka, Krzysztof Tutaj, Tomasz Mróz, Marian Wielosz, Roman Mądro & Piotr Tutka. (2011) Low dose of bupropion significantly enhances the anticonvulsant activity of felbamate, lamotrigine and topiramate in mice. European Journal of Pharmacology 650:2-3, pages 550-555.
Crossref
Crossref
Robert E. Sorge & Paul B. S. Clarke. 2011. Animal Models of Drug Addiction. Animal Models of Drug Addiction
101
132
.
Paul M. O’Byrne, Robert Williams, John J. Walsh & John F. Gilmer. (2010) The aqueous stability of bupropion. Journal of Pharmaceutical and Biomedical Analysis 53:3, pages 376-381.
Crossref
Crossref
Donald J. AbrahamRichard A. Glennon & Leslie Iversen. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
219
264
.
M. Imad Damaj, Sheri D. Grabus, Hernan A. Navarro, Robert E. Vann, Jonathan A. Warner, Lindsey S. King, Jenny L. Wiley, Bruce E. Blough, Ronald J. Lukas & F. Ivy Carroll. (2010) Effects of Hydroxymetabolites of Bupropion on Nicotine Dependence Behavior in Mice. Journal of Pharmacology and Experimental Therapeutics 334:3, pages 1087-1095.
Crossref
Crossref
Trevor Grinter. 2010. Green Chemistry in the Pharmaceutical Industry. Green Chemistry in the Pharmaceutical Industry
197
219
.
Leah M Hesse, Yumiko Sakai, Daesety Vishnuvardhan, Albert P Li, Lisa L von Moltke & David J Greenblatt. (2003) Effect of bupropion on CYP2B6 and CYP3A4 catalytic activity, immunoreactive protein and mRNA levels in primary human hepatocytes: comparison with rifampicin. Journal of Pharmacy and Pharmacology 55:9, pages 1229-1239.
Crossref
Crossref
Neil E. Paterson. (2009) Behavioural and pharmacological mechanisms of bupropion's anti-smoking effects: Recent preclinical and clinical insights. European Journal of Pharmacology 603:1-3, pages 1-11.
Crossref
Crossref
Peter H Silverstone, Robert Williams, Louis McMahon, Rosanna Fleming & Siobhan Fogarty. (2008) Convulsive liability of bupropion hydrochloride metabolites in Swiss albino mice. Annals of General Psychiatry 7:1.
Crossref
Crossref
Robert L. Walsky & R. Scott Obach. (2007) A Comparison of 2-Phenyl-2-(1-piperidinyl)propane (PPP), 1,1′,1″-Phosphinothioylidynetrisaziridine (ThioTEPA), Clopidogrel, and Ticlopidine as Selective Inactivators of Human Cytochrome P450 2B6. Drug Metabolism and Disposition 35:11, pages 2053-2059.
Crossref
Crossref
Anna M. Lee, Christopher Jepson, Ewa Hoffmann, Leonard Epstein, Larry W. Hawk, Caryn Lerman & Rachel F. Tyndale. (2007) CYP2B6 Genotype Alters Abstinence Rates in a Bupropion Smoking Cessation Trial. Biological Psychiatry 62:6, pages 635-641.
Crossref
Crossref
Aleksanteri Petsalo, Miia Turpeinen & Ari Tolonen. (2007) Identification of bupropion urinary metabolites by liquid chromatography/mass spectrometry. Rapid Communications in Mass Spectrometry 21:16, pages 2547-2554.
Crossref
Crossref
Jean-Noël Volle, Nikolay Kaloyanov, Mohamed Chiheb Saada, David Virieux & Jean-Luc Pirat. (2007) Phosphinyl analogues of hydroxybupropion: (±)-2-aryl-3,3,5,5-tetramethyl-[1,4,2]-oxazaphosphinanes. Tetrahedron Letters 48:27, pages 4695-4697.
Crossref
Crossref
Sonja K Billes & Michael A Cowley. (2006) Inhibition of Dopamine and Norepinephrine Reuptake Produces Additive Effects on Energy Balance in Lean and Obese Mice. Neuropsychopharmacology 32:4, pages 822-834.
Crossref
Crossref
Hongmei Xu, Katarzyna K. Loboz, Annette S. Gross & Andrew J. McLachlan. (2006) Stereoselective analysis of hydroxybupropion and application to drug interaction studies. Chirality 19:3, pages 163-170.
Crossref
Crossref
Linda P. Dwoskin, Anthony S. Rauhut, Kelley A. King‐Pospisil & Michael T. Bardo. (2007) Review of the Pharmacology and Clinical Profile of Bupropion, an Antidepressant and Tobacco Use Cessation Agent. CNS Drug Reviews 12:3-4, pages 178-207.
Crossref
Crossref
Jean-Noël Volle, David Virieux, Matthieu Starck, Jérôme Monbrun, Ludovic Clarion & Jean-Luc Pirat. (2006) Chiral phosphinyl analogues of 2-C-arylmorpholinols: 2-aryl-3,5-diphenyl-[1,4,2]-oxazaphosphinanes. Tetrahedron: Asymmetry 17:9, pages 1402-1408.
Crossref
Crossref
Aberra Fura. (2006) Role of pharmacologically active metabolites in drug discovery and development. Drug Discovery Today 11:3-4, pages 133-142.
Crossref
Crossref
Katarzyna K. Loboz, Annette S. Gross, John Ray & Andrew J. McLachlan. (2005) HPLC assay for bupropion and its major metabolites in human plasma. Journal of Chromatography B 823:2, pages 115-121.
Crossref
Crossref
M. Imad Damaj, F. Ivy Carroll, J. Brek Eaton, Hernan A. Navarro, Bruce E. Blough, Sadiq Mirza, Ronald J. Lukas & Billy R. Martin. (2004) Enantioselective Effects of Hydroxy Metabolites of Bupropion on Behavior and on Function of Monoamine Transporters and Nicotinic Receptors. Molecular Pharmacology 66:3, pages 675-682.
Crossref
Crossref
Richard A. Glennon. 2004.
55
123
.
Mikhail L Bondarev, Tatiana S Bondareva, Richard Young & Richard A Glennon. (2003) Behavioral and biochemical investigations of bupropion metabolites. European Journal of Pharmacology 474:1, pages 85-93.
Crossref
Crossref
Donald J. AbrahamLeslie Iversen & Richard A. Glennon. 2003. Burger's Medicinal Chemistry and Drug Discovery. Burger's Medicinal Chemistry and Drug Discovery
483
524
.
Richard Young & Richard A. Glennon. (2002) Nicotine and bupropion share a similar discriminative stimulus effect. European Journal of Pharmacology 443:1-3, pages 113-118.
Crossref
Crossref
Simon Xi-Ming Li, Kenneth W Perry & David T Wong. (2002) Influence of fluoxetine on the ability of bupropion to modulate extracellular dopamine and norepinephrine concentrations in three mesocorticolimbic areas of rats. Neuropharmacology 42:2, pages 181-190.
Crossref
Crossref
Qun K Fang, Zhengxu Han, Paul Grover, Donald Kessler, Chris H Senanayake*Stephen A Wald. (2000) Rapid access to enantiopure bupropion and its major metabolite by stereospecific nucleophilic substitution on an α-ketotriflate. Tetrahedron: Asymmetry 11:18, pages 3659-3663.
Crossref
Crossref
G. Evan Boswell, David L. Musso, Ann O. Davis, James L. Kelley, Francis E. Soroko & Barret R. Cooper. (2009) Synthesis, stereochemistry and anti‐tetrabenazine activity of bicyclo analogues of 2‐phenylmorpholines. Journal of Heterocyclic Chemistry 34:6, pages 1813-1820.
Crossref
Crossref
Raymond F. Suckow, Ming F. Zhang & Thomas B. Cooper. (1997) Enantiomeric Determination of the Phenylmorpholinol Metabolite of Bupropion in Human Plasma Using Coupled Achiral-Chiral Liquid Chromatography. Biomedical Chromatography 11:3, pages 174-179.
Crossref
Crossref
James L. Kelley, David L. Musso, G. Evan Boswell, Francis E. Soroko & Barrett R. Cooper. (1996)
(2
S
,3
S
,5
R
)-2-(3,5-Difluorophenyl)-3,5- dimethyl-2-morpholinol: A Novel Antidepressant Agent and Selective Inhibitor of Norepinephrine Uptake
. Journal of Medicinal Chemistry 39:2, pages 347-349.
Crossref
Crossref
Terence A. Ketter, Janice B. Jenkins, David H. Schroeder, Peggy J. Pazzaglia, Lauren B. Marangell, Mark S. George, Ann M. Callahan, Melvin L. Hinton, John Chao & Robert M. Post. (1995) Carbamazepine but not Valproate Induces Bupropion Metabolism. Journal of Clinical Psychopharmacology 15:5, pages 327-333.
Crossref
Crossref
G. Laux, A. Delini-Stula, U. Breyer-Pfaff, J. Demling, D. Ebert, W. Pöldinger, S. Kasper, M. Osterheider, O. Dietmaier, H.-J. Möller & J. Fuger. 1993. Neuro-Psychopharmaka. Neuro-Psychopharmaka
105
268
.
John A. Hill & Jeffrey D. Scharver. (2006) Syntheses of carbon‐14 and tritium labelled forms of bupropion hydrochloride – a novel antidepressant. Journal of Labelled Compounds and Radiopharmaceuticals 25:10, pages 1095-1104.
Crossref
Crossref
Juzar S. Kaka, Khalil I. Al-Khamis & Musbah O. M. Tanira. (1988) Effect of hepatic and renal dysfunction on disposition of Bupropion in rats. European Journal of Drug Metabolism and Pharmacokinetics 13:3, pages 149-153.
Crossref
Crossref